Esperoct FDA Approval History
Last updated by Judith Stewart, BPharm on May 19, 2020.
FDA Approved: Yes (First approved February 19, 2019)
Brand name: Esperoct
Generic name: antihemophilic factor (recombinant) glycopegylated-exei
Previous name: turoctocog alfa pegol
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Hemophilia A
Esperoct (antihemophilic factor [recombinant] glycopegylated-exei) is an extended half-life factor VIII molecule that may be used to treat or prevent bleeding episodes in adults and children with hemophilia A.
Development timeline for Esperoct
| Date | Article |
|---|---|
| Feb 19, 2019 | Approval FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.